• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
SUPN

SUPN

Supernus Pharmaceuticals, Inc.

NASDAQHealthcareDrug Manufacturers - Specialty & GenericUS

USD44.03

-0.04 (-0.08%)

Rating:C+

Company Profile

CEO

Jack A. Khattar

IPO Date

2012-05-01

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Exchange

NASDAQ

Country

US

Market Metrics

Open

$43.93

Prev. Close

$44.07

Day Low

$43.48

Day High

$44.98

52W Low

$30.83

52W High

$59.68

Market Cap

$2.56B

Volume

0.96M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

21.5%

Avg Negative

4.9%

Avg Neutral

73.4%

News Feed

Supernus to Host Second Quarter 2021 Financial Results Conference Call

GlobeNewsWire·7/22/2021·↑ positive

Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment

Seeking Alpha·6/2/2021·↑ positive

Supernus to Present at Jefferies Virtual Healthcare Conference

GlobeNewsWire·5/25/2021·↑ positive

Supernus Pharmaceuticals: Virtuous Cycle Of Free Cash Flow Generation To Fund Product Development And Acquisition

Seeking Alpha·5/13/2021·↑ positive

Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/5/2021·↓ negative

Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Miss Estimates

Zacks Investment Research·5/5/2021·↑ positive

Supernus Announces Paragraph IV ANDA Filing for XADAGO®

GlobeNewsWire·5/4/2021·↑ positive

Supernus to Host First Quarter 2021 Financial Results Conference Call

GlobeNewsWire·4/27/2021·↓ negative

Supernus (SUPN) Receives FDA Approval for ADHD Treatment

Zacks Investment Research·4/5/2021·↑ positive

Why Supernus Pharmaceuticals Stock Is Soaring Today

The Motley Fool·4/5/2021·↑ positive